RHHBY - Oncolytics Bio teams up with Roche in gastrointestinal cancer trial

Oncolytics Biotech (ONCY) launches a new multi-indication gastrointestinal ((GI)) cancer study to be managed by AIO, an academic cooperative medical oncology group based in Germany.The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq), in patients with metastatic pancreatic, colorectal and advanced anal cancers.The GOBLET study will make use of a new master clinical supply agreement between Oncolytics and Roche. Per the agreement, Roche will supply atezolizumab for use in Oncolytics' clinical development plan. The primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T cell clonality and CEACAM6) as exploratory endpoints. Approx. 55 patients are planned for enrollment across four separate cohorts.ONCY shares +7% premarket.

For further details see:

Oncolytics Bio teams up with Roche in gastrointestinal cancer trial